NovaBay Pharmaceuticals Announces New Partner Pharmacy Program
15 April 2019 - 8:50PM
Business Wire
Affirms long-term commitment to make Avenova
convenient for both eye care specialists and patients
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company, announces a new pharmacy partnering
program in a continued effort to ensure all patients in the U.S.
have reliable and affordable access to prescription Avenova®.
NovaBay has recently added six new pharmacies as Avenova channel
partners. The company’s pharmacy partners serve patients across the
U.S., and together ensure patients in all 50 states have convenient
access to Avenova.
Eyecare professionals can call 800-890-0329 or
email sales@avenova.com to learn more about their local
pharmacy partner.
By contracting directly with these pharmacies, patients are
guaranteed to receive the best pricing and quality service when
filling their Avenova prescriptions. “Our commitment to a quality
patient experience, along with our expanding national presence
ensures every patient who wants Avenova can obtain it at the best
price,” said Dan Richards, CEO of Meds In Motion Pharmacy, one of
Avenova’s channel partners.
NovaBay’s pharmacy partners enhance the process for eye care
professionals to easily and confidently prescribe Avenova. This is
vital for physicians like Dr. Stephen Wilmarth of Wilmarth Eye and
Laser Center in Roseville, Calif., who rely on Avenova for their
patients. “Avenova is the mainstay of my dry eye practice. There’s
no clear alternative. Even if patients are not improving on other
treatments, I find Avenova works. Patient acceptance is very high
because Avenova feels so soothing immediately upon application,”
said Dr. Wilmarth.
About Avenova®
Avenova is an eye care product formulated with our proprietary,
stable and pure form of hypochlorous acid. Avenova is designed for
removal of the microorganisms and debris that contribute to
conditions such as meibomian gland dysfunction, dry eye and
blepharitis. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct
salesforce.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our business strategies and future
focus, our estimated future revenue, and generally the company’s
expected future financial results. These statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the potential impact of the partner
pharmacy program and market potential of our products. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress:Like us
on FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us on Google+Visit
NovaBay’s Website
To dispense from your
practice:For NovaBay Avenova purchasing
information:Please call 800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190415005110/en/
NovaBay ContactJustin
HallInterim President and Chief Executive
Officer510-899-8800jhall@novabay.com
Investor ContactLHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024